Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/10010
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BUYSE, Marc | - |
dc.date.accessioned | 2009-11-20T15:54:15Z | - |
dc.date.available | 2009-11-20T15:54:15Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | CANCER JOURNAL, 15(5). p. 421-425 | - |
dc.identifier.issn | 1528-9117 | - |
dc.identifier.uri | http://hdl.handle.net/1942/10010 | - |
dc.description.abstract | This article discusses statistical approaches to the validation of surrogate biomarkers and endpoints. One approach that has been successfully used in oncology consists of estimating associations at two levels: the association between the surrogate and the clinical endpoint, called the individual-level association, and the association between the effects of treatment on the surrogate and the clinical endpoint, called the trial-level association. This approach requires data to be available from multiple randomized trials, such as in a meta-analysis of trials based on individual patient data. The approach is illustrated using randomized trials of first-line treatments for advanced tumors of the colon, breast, ovary, and prostate. Data from several meta-analyses suggest that progression-free survival is an acceptable surrogate in advanced colorectal and ovarian cancer, but not in breast and prostate cancer. | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject.other | meta-analysis; surrogate endpoint; biomarker; colorectal cancer; breast cancer; ovarian cancer; prostate cancer | - |
dc.title | Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 425 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 421 | - |
dc.identifier.volume | 15 | - |
local.format.pages | 5 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Buyse, Marc] IDDI, B-1340 Louvain, Belgium. [Buyse, Marc] Hasselt Univ, Ctr Stat, I BioStat, Diepenbeek, Belgium. | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.isi | 000270918300012 | - |
item.fullcitation | BUYSE, Marc (2009) Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials. In: CANCER JOURNAL, 15(5). p. 421-425. | - |
item.fulltext | No Fulltext | - |
item.contributor | BUYSE, Marc | - |
item.validation | ecoom 2010 | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 1528-9117 | - |
crisitem.journal.eissn | 1540-336X | - |
Appears in Collections: | Research publications |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.